This federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Amgen USA Inc. The $1,052,008,540.28 definitive, firm-fixed price contract is for the delivery of an FDA-approved thrombopoietin receptor agonist drug to be used in the Strategic National Stockpile to treat thrombocytopenia (low platelet count) resulting from acute radiation syndrome in the event of a radiological or nuclear mass casualty incident. The contract has a 120-month period of performance, including a 60-month base period. There was no set-aside designation for this procurement, which was originally announced via a pre-solicitation notice on SAM.gov. Amgen USA Inc. is a leading biotechnology company that has been active in federal contracting, holding multiple Federal Supply Schedule and single-award indefinite delivery contracts with the Department of Veterans Affairs and other agencies for pharmaceutical products.
Generated 9/28/24, 9:30 AM